Talk about a strong second half. Generic-drug maker Mylan
Much of that growth can be traced back to sales of generic drugs in the U.S., which for the third quarter increased 17% year over year. Generic-drug makers the size of Mylan, Watson Pharmaceuticals
For Mylan, three drugs -- generic versions of Boehringer Ingelheim's Catapres-TTS, Astellas' Prograf, and Medicis Pharmaceutical's
Unfortunately, all good things come to an end. This time last year, Mylan was raving about its generic version of Abbott Labs'
The solution, of course, is to just keep launching new drugs, which is a little easier said than done. Mylan has a good track record, which investors should take into account, but ultimately they should be prepared for the potential of unsteady earnings.
If you can't handle the roller coaster, consider investing in a larger generic-drug maker like Teva Pharmaceutical
Fool analyst Jim Mueller recently picked Teva for our 11 O'Clock Stock series.
Novartis and Dr. Reddy's Laboratories are Motley Fool Global Gains picks. The Fool owns shares of Teva Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.